natgillin/translations-raw huggingface dataset:
- if you develop severe diarrhoea or vomiting, as these conditions may limit the effectiveness of this medicine. 
- ako dobijete teški proljev ili povraćate, jer ta stanja mogu ograničiti učinkovitost ovog lijeka;
Children Posaconazole AHCL should not be used in children (17 years of age and younger). 
Posakonazol AHCL se ne smije primjenjivati u djece (u dobi od 17 godina i mlađe).
- a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol. 
- „statin” kao što je simvastatin, atorvastatin ili lovastatin koji se primjenjuju za liječenje visokog kolesterola.
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Spain 
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Španjolska
Effect of food on oral absorption in healthy volunteers 
Utjecaj hrane na apsorpciju nakon peroralne primjene u zdravih dobrovoljaca
To improve absorption of posaconazole, whenever possible it should be taken during or immediately after food or a nutritional drink (see section 3 “How to take Posaconazole AHCL”). 
Kako bi se poboljšala apsorpcija posakonazola, treba ga, kad god je moguće, uzimati tijekom ili neposredno nakon obroka ili nutritivnog napitka (vidjeti dio 3 „Kako uzimati Posakonazol AHCL“).
EXP Discard after 30 days of opening. 
EXP Baciti po isteku 30 dana nakon otvaranja.
You should not take this medicine if you have a condition called glucose-galactose malabsorption and should take note of this amount of glucose if you need to watch your sugar intake for any reason. 
Nemojte uzimati ovaj lijek ako imate poremećaj malapsorpcije glukoze i galaktoze, a trebate uzeti u obzir ovu količinu glukoze ako iz bilo kojeg razloga morate kontrolirati unos šećera.
The filled and sealed bottle is packed into a carton along with a graduated polystyrene spoon (2.5 mL and 5 mL) for dispensing and administration of the suspension. 
Napunjena i zatvorena boca pakirana je u kartonsku kutiju zajedno sa žličicom od graduiranog polistirena (od 2,5 ml i 5 ml) za doziranje i primjenu suspenzije.
Pharmacokinetic / Pharmacodynamic relationships A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed. 
Farmakokinetički/farmakodinamički odnosi Opažena je korelacija između ukupne izloženosti lijeku podijeljene s najmanjom inhibitornom koncentracijom (AUC/MIK) i kliničkog ishoda.
However, this was not a prospective, randomised controlled study and so all comparisons with the external control group should be viewed with caution. 
randomizirano, kontrolirano ispitivanje, svaku se usporedbu s vanjskom kontrolnom skupinom mora razmotriti uz oprez.
In Study 316, overall mortality was similar (POS, 25 %; FLU, 28 %); however, the proportion of IFIrelated deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413). 
Ispitivanju 316 utvrđen je sličan ukupni mortalitet (POS, 25%; FLU, 28%); međutim, udio smrti povezanih s IGI bio je značajno niži u skupini koja je uzimala POS (4/301) nego u skupini koja je primala FLU (12/299; p=0,0413).
Your doctor will monitor your response and condition to determine how long Posaconazole AHCL needs to be given and whether any change is needed to your daily dose. 
Liječnik će pratiti Vaš odgovor na liječenje i Vaše stanje kako bi odredio koliko dugo morate uzimati Posakonazol AHCL i jesu li potrebne neke promjene dnevne doze.
The duration of therapy is based on recovery from neutropenia or immunosuppression. 
Trajanje liječenja temelji se na oporavku od neutropenije ili imunosupresije.
- Do not use this medicine after the expiry date which is stated on the label. 
- Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici iza oznake
Overall Response Success by Species All mycologically confirmed Aspergillus spp.1 
Uspjeh prema vrstama uzročnika Sve mikološki potvrđene vrste roda Aspergillus1
Posaconazole is slowly eliminated with a mean half-life (t½) of 35 hours (range 20 to 66 hours). 
Posakonazol se sporo eliminira, uz srednji poluvijek (t½) od 35 sati (raspon: 20 do 66 sati).
Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomization, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P= 0.0354) as well as IFI-related deaths (P = 0.0209). 
Na temelju KaplanMeierovih procjena, vjerojatnost preživljenja do 100. dana nakon randomizacije bila je značajno veća u bolesnika koji su primali posakonazol; taj se koristan utjecaj na preživljenje pokazao kada je analiza obuhvatila sve uzroke smrti (p=0,0354) kao i smrti povezane s invazivnim gljivičnim infekcijama (p=0,0209).
The following medicines may decrease the effectiveness of Posaconazole AHCL by decreasing the amount of Posaconazole AHCL in the blood: - rifabutin and rifampicin (used to treat certain infections). 
Sljedeći lijekovi mogu smanjiti učinkovitost lijeka Posakonazol AHCL tako što smanjuju njegovu količinu u krvi: - rifabutin i rifampicin (primjenjuju se za liječenje nekih infekcija).
There is no information on the effect of alcohol on posaconazole." 
Nema podataka o utjecaju alkohola na posakonazol.
Opening date:_________ 
Datum otvaranja:
White to off-white free flowing suspension. 
OBLIK Oralna suspenzija Bijela do bjelkasta suspenzija.
The majority (377/600, [63 %]) of patients included had Acute Grade 2 or 3 or chronic extensive (195/600, [32.5%]) GVHD at study start. 
Većina uključenih bolesnika (377/600, [63%]) je na početku ispitivanja imala akutni GVHD stupnja 2 ili 3 ili kronični opsežni GVHD (195/600, [32,5%]).
Look at the list of medicines given above that must not be taken while you are taking Posaconazole AHCL. 
Pročitajte gore navedeni popis lijekova koji se ne smiju uzimati dok uzimate Posakonazol AHCL.
Elderly (≥ 65 years) An increase in Cmax (26 %) and AUC (29 %) was observed in elderly subjects (24 subjects ≥ 65 years of age) relative to younger subjects (24 subjects 18 - 45 years of age). 
Stariji (65 godina) Opažen je porast Cmax (26%) i AUC-a (29%) u starijih ispitanika (24 ispitanika 65 godina) u odnosu na mlađe ispitanike (24 ispitanika u dobi 18-45 godina).
In addition to the medicines named above there are other medicines that carry a risk of rhythm problems that may be greater when they are taken with Posaconazole AHCL. 
Pored gore navedenih lijekova postoje i drugi lijekovi koji nose rizik od nastanka poteškoća sa srčanim ritmom, koji se može povećati ako se uzimaju s lijekom Posakonazol AHCL.
Tabulated list of adverse reactions Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known. 
Unutar klasifikacije organskih sustava, nuspojave su navedene prema učestalosti pojavljivanja definiranoj kao: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole AHCL should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm3. 
U bolesnika s akutnom mijeloičnom leukemijom ili mijelodisplastičnim sindromima profilaksu lijekom Posakonazol AHCL treba započeti nekoliko dana prije očekivanog nastupa neutropenije i nastaviti još 7 dana nakon što broj neutrofila poraste na više od 500 stanica po mm3.
What Posaconazole AHCL looks like and contents of the pack Posaconazole AHCL is a white to off-white free flowing suspension, packaged in amber glass bottle. 
Kako Posakonazol AHCL izgleda i sadržaj pakiranja Posakonazol AHCL je bijela do bjelkasta suspenzija, pakirana u smeđoj (jantarnoj) staklenoj boci.
Food The absorption of posaconazole is significantly increased by food (see sections 4.2 and 5.2). 
Hrana značajno povećava apsorpciju posakonazola (vidjeti dijelove 4.2 i 5.2).
The table below shows the recommended dose and length of treatment which depend on the type of infection that you have and may be individually adapted for you by your doctor. 
Tablica ispod prikazuje preporučene doze i trajanje liječenja, koje ovise o vrsti infekcije koju imate i
- infections in the mouth or throat area (known as “thrush”) caused by fungi called Candida, which were not previously treated. 
- infekcija u području usta ili grla (tzv. „mliječac“) prouzročenih gljivicom Candida, koje nisu prethodno liječene.
There is no special treatment available in the case of overdose with posaconazole. 
Nema posebnog dostupnog liječenja u slučaju predoziranja posakonazolom.
Overall efficacy of posaconazole oral suspension at the end of treatment for invasive aspergillosis in comparison to an external control group 
Ukupna djelotvornost posakonazol oralne suspenzije na završetku liječenja invazivne aspergiloze u usporedbi s vanjskom kontrolnom skupinom Posakonazol oralna suspenzija
Do not take Posaconazole AHCL if any of the above apply to you. 
Nemojte uzimati Posakonazol AHCL ako se nešto od gore navedenog odnosi na Vas.
The elimination half-life (t1/2) was prolonged from approximately 27 hours up to ~43 hours in respective groups. 
Poluvijek eliminacije (t½) je u odgovarajućim skupinama produljen sa približno 27 sati na ~ 43 sata.
Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies. 
Stoga treba ciljati da najniža koncentracija sirolimusa bude u gornjem dijelu uobičajenog raspona terapijskih vrijednosti, te u tom smislu treba pomno pratiti kliničke znakove i simptome, laboratorijske nalaze i nalaze biopsije tkiva.
At exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability. 
Pri izloženosti manjoj od one koja se postiže terapijskim dozama u ljudi posakonazol je prouzročio koštane varijacije i malformacije, distociju, produljeno trajanje gestacije, smanjenu srednju veličinu okota i smanjenu sposobnost postnatalnog preživljavanja.
Posaconazole AHCL contains approximately 1.75g of glucose per 5mLof suspension. 
Posakonazol AHCL sadrži približno 1,75 g glukoze u 5 ml suspenzije.
Posaconazole AHCL with food and drink 
Posakonazol AHCL s hranom i pićem
After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose). 
Nakon primjene 14C-posakonazola, radioaktivnost se uglavnom otkrila u stolici (77% radioaktivno označene doze), a glavnu je komponentu činio izvorni spoj (66% radioaktivno označene doze).
Posaconazole is also available as 100 mg gastro-resistant tablet and 300 mg concentrate for solution for infusion. 
Posakonazol je također dostupan u obliku želučanootpornih tableta od 100 mg i koncentrata za otopinu za infuziju od 300 mg.
Do not take Posaconazole AHCL if you are pregnant unless you are told to by your doctor. 
Nemojte uzeti Posakonazol AHCL ako ste trudni, osim ako
The critical ratio for subjects with Aspergillus infections was ~200. 
Kritična vrijednost navedenog omjera za ispitanike s infekcijama čiji je uzročnik bio Aspergillus iznosila je ~200.
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), efavirenz and cimetidine 
Rifamicinski antibiotici (rifampicin, rifabutin), određeni antikonvulzivi (fenitoin, karbamazepin, fenobarbital, primidon), efavirenz i cimetidin
- Candida albicans: S ≤0.06 mg/L, R >0.06 mg/L - Candida tropicalis: S ≤0.06 mg/L, R >0.06 mg/L - Candida parapsilosis: S ≤0.06 mg/L, R >0.06 mg/L 
(R)], su: - Candida albicans: S ≤0,06 mg/l, R >0,06 mg/l - Candida tropicalis: S ≤0,06 mg/l, R >0,06 mg/l
No clinically relevant changes in the mean QTc (Fridericia) interval from baseline were observed. 
Nisu opažene klinički značajne promjene srednje vrijednosti QTc-intervala (Fridericia) u odnosu na početne vrijednosti.
Caution should be used when prescribing Posaconazole AHCL to patients with hypersensitivity to other azoles. 
Potreban je oprez kad se Posakonazol AHCL propisuje bolesnicima preosjetljivima na druge azole.
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended. 
Ako se ovi lijekovi primjenjuju istodobno, preporučuje se pomno nadzirati kompletnu krvnu sliku kao i nuspojave povezane s povećanom koncentracijom rifabutina (npr. uveitis).
This medicine contains less than 1 mmol sodium (23 mg) per 5 mL of suspension, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po 5 ml suspenzije, tj. zanemarive količine natrija.
In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16 %) vs. FLU/ITZ 67/298 (22 %) p= 0.048]. 
1899d 316d posakonazola [POS 49/304 (16%) naspram FLU/ITZ 67/298 (22%) p=0,048].
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %. 
U jednom ispitivanju u zdravih dobrovoljaca, posakonazol oralna suspenzija (200 mg jedanput na dan tijekom 10 dana) povećala je izloženost (AUC) intravenski primijenjenog midazolama (0,05 mg/kg) za 83%.
Do not switch between taking Posaconazole tablets and posaconazole oral suspension without talking to your doctor or pharmacist because it may result in a lack of efficacy or an increased risk of adverse reactions. 
Nemojte prijeći s tableta posakonazola na oralnu suspenziju posakonazola ili obrnuto bez razgovora s liječnikom ili ljekarnikom jer to može dovesti do smanjenja djelotvornosti lijeka i povećanog rizika za pojavu nuspojava.
There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea). 
Gastrointestinalna disfunkcija Farmakokinetički podaci u bolesnika s teškom gastrointestinalnom disfunkcijom (npr. jakim proljevom) su ograničeni.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of oral suspension contains 40 mg of posaconazole. 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml oralne suspenzije sadrži 40 mg posakonazola.
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. 
Rifabutin Posakonazol je povećao Cmax rifabutina za 31%, a AUC za 72%.
Patients were treated with posaconazole or fluconazole oral suspension (both posaconazole and fluconazole were given as follows: 100 mg twice a day for 1 day followed by 100 mg once a day for 13 days). 
Bolesnici su liječeni posakonazolom ili flukonazolom u obliku oralne suspenzije (oba lijeka posakonazol i flukonazol su se primjenjivala na sljedeći način: 100 mg dvaput na dan 1. dana, a nakon toga 100 mg jedanput na dan tijekom 13 dana).
In subjects with severe renal impairment (n=6, Cl cr< 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV]. 
U ispitanika s teškim oštećenjem funkcije bubrega (n=6, CIcr<20 ml/min/1,73 m2), AUC posakonazola jako je varirao [>96% CV (koeficijent varijabilnosti)] u usporedbi s drugim kategorijama bubrežne funkcije [<40% CV].
Discard after 30 days of opening. 
Baciti po isteku 30 dana nakon otvaranja.
Each dose of Posaconazole AHCL should be administered during or immediately after a meal, or a nutritional supplement in patients who cannot tolerate food to enhance the oral absorption and to ensure adequate exposure. 
Svaka doza lijeka Posakonazol AHCL mora se primijeniti tijekom ili neposredno nakon obroka, odnosno nadomjeska prehrani u bolesnika koji ne podnose hranu, kako bi se poboljšala oralna apsorpcija i osigurala primjerena izloženost lijeku.
Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects: 
Obavijestite liječnika, ljekarnika ili medicinsku sestru ako primijetite neku od sljedećih nuspojava:
Posaconazole is excreted into the milk of lactating rats (see section 5.3). 
Dojenje Posakonazol se izlučuje u mlijeko ženki štakora tijekom laktacije (vidjeti dio 5.3).
Steady-state is attained following 7 to 10 days of multiple-dose administration. 
Stanje dinamičke ravnoteže postiže se nakon 7 do 10 dana primjene ponovljenih doza.
Do not take Posaconazole AHCL - if you are allergic to posaconazole or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na posakonazol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
- if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine, or a “statin” such as simvastatin, atorvastatin or lovastatin 
• ako uzimate terfenadin, astemizol, cisaprid, pimozid, halofantrin, kinidin, bilo koji lijek koji sadrži ergot alkaloide kao što su ergotamin ili dihidroergotamin ili statine kao što su simvastatin, atorvastatin ili lovastatin.
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively. 
Rifabutin (300 mg jedanput na dan) je snizio Cmax (maksimalna koncentracija u plazmi) posakonazola na 57%, a AUC (površina ispod krivulje koncentracija u plazmi-vrijeme) na 51%.
- bleeding into your stomach or gut - signs include vomiting blood or passing blood in your stool - a blockage in your gut (intestinal obstruction) especially in the “ileum”. 
- krvarenje u želudac ili crijeva - znakovi uključuju povraćanje krvi ili krv u stolici - blokada crijeva (opstrukcija crijeva), osobito završnog dijela tankog crijeva (ileum).
- some medicines used to treat or prevent fits including; phenytoin, carbamazepine, phenobarbital or primidone). 
- neki lijekovi koji se primjenjuju u liječenju ili sprječavanju napadaja, uključujući fenitoin, karbamazepin, fenobarbital ili primidon.
Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure. 
Farmakokinetičko modeliranje provedeno s lijekom u obliku tableta za peroralnu primjenu upućuje na to da bi izloženost posakonazolu mogla biti manja u bolesnika tjelesne težine veće od 120 kg.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. 
Nakon primjene jednokratne doze posakonazol oralne suspenzije, blago ili umjereno oštećenje funkcije bubrega (n=18, CIcr ≥ 20 ml/min/1,73 m2) nije utjecalo na farmakokinetiku posakonazola, pa nije potrebna prilagodba doze.
Co-administration of posaconazole with proton pump inhibitors should be avoided if possible. 
Ako je moguće, istodobnu primjenu posakonazola i inhibitora protonske pumpe potrebno je izbjegavati.
The primary packaging is an amber glass bottle (Type III) closed with a child-resistant and tamper evident polypropylene cap. 
Unutarnje pakiranje je smeđa (jantarna) staklena boca (tip III) zatvorena zatvaračem sigurnim za djecu i zaštitnom polipropilenskom kapicom s evidencijom otvaranja.
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). 
Istodobnu primjenu posakonazola i rifabutina potrebno je izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja (o učinku rifabutina na koncentraciju posakonazola u plazmi vidjeti također u gornjem tekstu).
Do not take Posaconazole AHCL if you are taking any of the following: - terfenadine (used to treat allergies) - astemizole (used to treat allergies) - cisapride (used to treat stomach problems) - pimozide (used to treat symptoms of Tourette's and mental illness) - halofantrine (used to treat malaria) - quinidine (used to treat abnormal heart rhythms). 
Nemojte uzimati Posakonazol AHCL ako uzimate neki od sljedećih lijekova: - terfenadin (primjenjuje se za liječenje alergija); - astemizol (primjenjuje se za liječenje alergija); - cisaprid (primjenjuje se za liječenje želučanih tegoba); - pimozid (primjenjuje se za liječenje simptoma Touretteovog sindroma i duševne bolesti); - halofantrin (primjenjuje se za liječenje malarije); - kinidin (primjenjuje se za liječenje poremećaja srčanog ritma).
The clinical response rates from the above study are shown in the Table 4 below. 
Stope kliničkog odgovora u ovom ispitivanju prikazane su u Tablici
If you take more Posaconazole AHCL than you should If you are concerned that you may have taken too much, contact your doctor or healthcare professional immediately. 
Ako uzmete više lijeka Posakonazol AHCL nego što ste trebali Ako mislite da ste uzeli previše lijeka Posakonazol AHCL, odmah se obratite liječniku ili drugom zdravstvenom radniku.
If you develop severe diarrhoea or vomiting (being sick) while taking Posaconazole AHCL, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly. 
Ako dobijete teški proljev ili povraćate dok uzimate Posakonazol AHCL, odmah se obratite svom liječniku, ljekarniku ili medicinskoj sestri, jer to može narušiti ispravno djelovanje Posakonazol AHCLa.
Posaconazole AHCL must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5). 
Posakonazol AHCL ne smije se primjenjivati s lijekovima koji su supstrati enzima CYP3A4 i za koje je poznato da produljuju QTcinterval (vidjeti dijelove 4.3 i 4.5).
Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb 
Posakonazol oralna suspenzija Kontrolna skupinaa Udio (%) bolesnika s dokazanom/vjerojatnom aspergilozom
You may feel dizzy, sleepy, or have blurred vision while taking Posaconazole AHCL, which may affect your ability to drive or use tools or machines. 
Dok uzimate Posakonazol AHCL, možete osjetiti omaglicu, pospanost ili imati zamućen vid, što može utjecati na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL). 
Nakon primjene 800 mg posakonazola na dan, raspodijeljeno u više doza, za liječenje invazivnih gljivičnih infekcija srednja vrijednost najnižih koncentracija posakonazola u plazmi 12 bolesnika u dobi 8-17 godina (776 ng/ml) bila je slična onoj u 194 bolesnika u dobi 18-64 godina (817 ng/ml).
If you become pregnant while you are taking Posaconazole AHCL, contact your doctor straight away. 
Ako zatrudnite tijekom liječenja lijekom Posakonazol AHCL, odmah se obratite svom liječniku.
Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism. 
Posakonazol može povećati koncentraciju ergot alkaloida (ergotamina i dihidroergotamina) u plazmi,
c: In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline. 
Ispitivanju 1899 to je bilo razdoblje od randomizacije do 100 dana nakon randomizacije; u ispitivanju 316 to je bilo razdoblje od dana početka ispitivanja do 111. dana nakon toga.